The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study
Open accessAbstract
Context: Increase in drug frequency or dose is recommended for acromegaly patients with partial response to long-acting somatostatin receptor ligands (SRLs). However, the efficacy and safety data with lanreotide (LAN) Autogel (LAN-ATG) at high dose (HD) or high frequency (HF) are still scanty. Objective: To evaluate the biochemical efficacy and safety of HF and HD LAN-ATG in patients with active acromegaly. Design: Twenty-four-week prospective, multicenter, randomized, open-label trial. Patients and Interventions: Thirty patients with active acromegaly, partial responders to SRLs, were randomized to HF (120 mg/21 days; 15 patients) or HD (180 mg/28 days; 15 patients) LAN-ATG. Outcomes: Normalization of serum insulin-like growth factor-I (IGF-I) and reduction in random growth hormone (GH) values < 1.0 µg/L, reduction in serum IGF-I and GH from baseline, differences in biochemical response between HF and HD LAN-ATG, adverse events. Results: IGF-I decreased significantly (P = 0.007) during the 24-week treatment, with greater decrease in HD (P = 0.03) vs HF group (P = 0.08). Normalization in IGF-I values occurred in 27.6% of patients (P = 0.016 vs baseline), without a significant difference between HF and HD groups (P = 0.59). The decrease in serum IGF-I significantly correlated with serum LAN values (P = 0.04), and normalization of IGF-I was predicted by baseline IGF-I values (P = 0.02). Serum GH values did not change significantly (P = 0.22). Overall, 19 patients (63.3%) experienced adverse events, all being mild to moderate and transient, without differences between the two therapeutic arms. Conclusion: HF and HD LAN-ATG regimens are effective in normalizing IGF-I values in about one-third of patients with active acromegaly inadequately controlled by long-term conventional SRLs therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vertebral Fractures in Patients With Acromegaly: A 3-Year Prospective Study
Mazziotti, G., Bianchi, A., Porcelli, T., Mormando, M., Maffezzoni, F., Cristiano, A., Giampietro, A., De Marinis, L., & Giustina, A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1460 · Cited by 172
Self-citation
Cited by
Pituitary-Tumor Endocrinopathies
Melmed, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810772 · Cited by 604
A Consensus Statement on acromegaly therapeutic outcomes
Melmed, S., Bronstein, M. D., Chanson, P., Klibanski, A., Casanueva, F. F., Wass, J. A. H., Strasburger, C. J., Luger, A., Clemmons, D. R., & Giustina, A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0058-5 · Cited by 561
Self-citationColao, A., Grasso, L. F. S., Giustina, A., Melmed, S., Chanson, P., Pereira, A. M., & Pivonello, R. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0071-6 · Cited by 396
Self-citationMultidisciplinary management of acromegaly: A consensus
Giustina, A., Barkhoudarian, G., Beckers, A., Ben-Shlomo, A., Biermasz, N., Biller, B., Boguszewski, C., Bolanowski, M., Bollerslev, J., Bonert, V., et al. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09588-z · Cited by 347
Self-citationAcromegaly: pathogenesis, diagnosis, and management
Fleseriu, M., Langlois, F., Lim, D. S. T., Varlamov, E. V., & Melmed, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00244-3 · Cited by 279
Metadata
- Authors
- Giustina, A., Mazziotti, G., Cannavò, S., Castello, R., Arnaldi, G., Bugari, G., Cozzi, R., Ferone, D., Formenti, A. M., Gatti, E., Grottoli, S., Maffei, P., Maffezzoni, F., Montini, M., Terzolo, M., & Ghigo, E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2017-04-17
- Volume
- 102
- Issue
- 7
- Pages
- 2454-2464
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2605380660
- Cited by
- 71
- References
- 1
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.